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TGF-b induces proangiogenic and antiangiogenic factors via
parallel but distinct Smad pathways.
Background. Angiogenesis has a key role in numerous dis-
ease processes. One of the most important angiogenic fac-
tors is vascular endothelial growth factor (VEGF-A), whereas
thrombospondin-1 (TSP-1) is a major antiangiogenic factor.
Recent studies have shown that VEGF-A as well as TSP-1 is
regulated by transforming growth factor-b1 (TGF-b1), but the
mechanism remains unclear.
Methods. We examined the role of TGF-b1 and its signaling
pathways in mediating expression of these two molecules. Rat
proximal tubular cells (NRK52E) were stimulated with TGF-
b1 to induce VEGF-A and TSP-1 synthesis. To clarify roles of
receptor-activated Smads (R-Smads), we blocked Smad signal-
ing using overexpression of the inhibitory Smad, Smad7, and
by using fibroblasts from wild-type or knockout mice. To con-
firm the antiantigenic role of Smads, soluble Flt-1 regulation in
response to TGF-b1 was also examined. In addition, the effect
of conditioned media from NRK52E and Smad knockout cells
was examined on endothelial cell proliferation.
Results. Induction of VEGF-A and TSP-1 by TGF-b1 in
NRK52E cells was associated with activation of pathway-
restricted R-Smads (Smad2 and 3) and blocking these Smads by
overexpression of Smad7 blocked their induction. By using of
Smad knockout cells, Smad3 was shown to have a key role in the
stimulation of VEGF-A expression whereas Smad2 was criti-
cal for TSP-1 expression. Consistent with the hypothesis that
Smad2 has an antiangiogenic function, we also demonstrated
that Smad2, but not Smad3, mediated the expression of VEGF-
A antagonist, soluble VEGF-A receptor sFlt-1, in response to
TGF-b1. Conditioned media from NRK52E, which was stimu-
lated by TGF-b1 for 24 hours, did not induce endothelial cell
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proliferation. However, conditioned media from Smad2 knock-
out induced endothelial cell proliferation, whereas endothe-
lial cell proliferation was inhibited by Smad3 knockout-derived
conditioned media.
Conclusion. R-Smads have distinct roles in mediating the
expression of pro- and antiangiogenic growth factors in re-
sponse to TGF-b1.
Angiogenesis has a critical role in development, nor-
mal health, and disease. Impaired angiogenesis has been
linked to renal disease associated with aging [1] and
with renal progression [2], whereas excessive angiogene-
sis has been found in diabetic retinopathy [3] and in tumor
metastasis [4]. One of the most important proangiogenic
factors is vascular endothelial growth factor (VEGF-A)
[5–7], while thrombospondin-1 (TSP-1) is antiangiogenic
and has been shown to oppose VEGF-A actions [1, 2,
8, 9]. TSP-1 expression has also been linked to impaired
angiogenesis and aging-associated renal disease and pro-
gressive renal damage [1, 2, 10, 11]. Recently, a soluble
form of the VEGF-A receptor, sFlt-1, has been recog-
nized as the true natural inhibitor of VEGF-A [12, 13].
This soluble receptor (sFlt-1) has now been linked to con-
ditions associated with endothelial dysfunction, including
hypertension, heart failure, and preeclampsia [14, 15]. In
the latter condition, circulating sFlt-1 is thought to have a
key role in the pathogenesis of disease [14]. Thus, an un-
derstanding of the mechanisms regulating these growth
factors may provide insight into the prevention and treat-
ment of these conditions.
Transforming growth factor-b1 (TGF-b1) is known
to have a key role in many disease processes, includ-
ing diabetes [16, 17], cancer, aging [18–20], preeclampsia
[21, 22], and renal disease [23]. TGF-b1 is also known
to have both angiogenic and antiangiogenic actions de-
pending on the specific condition. TGF-b1 acts by stim-
ulating a complicated intracellular signaling pathway
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consisting of receptor-activated Smads (R-Smads2 and 3)
and inhibitory Smads (Smad6 and 7). Distinct roles for
each R-Smad have only been identified in the past few
years. In this paper we provide evidence that a major dif-
ference between Smad2 and Smad3 signaling relates to
their role in mediating the expression of pro- and antian-
giogenic molecules in response to TGF-b1. Smad3 has a
proangiogenic role and stimulates VEGF-A expression,
whereas Smad2 has an antiangiogenic role in mediating
TSP-1 and sFlt-1 expression. These data may provide an
explanation for the paradoxic roles of TGF-b1 in angio-
genesis in various disease states.
METHODS
Materials
TGF-b1 was ordered from R&D systems (Minneapo-
lis, MN, USA). Antibody reagents included mouse
monoclonal antibody to Smad2 (Transduction Labo-
ratories, Lexington, KY, USA), thrombospondin (TSP
Ab-4; A6.1) (NeoMarkers) (Lab Vision Co., Fremont,
CA, USA), and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) (Chemicon, Temecula, CA, USA) and
polyclonal antibodies to Smad7 (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA), Smad3 antibody
(Zymed Laboratory, Inc., South San Francisco, CA,
USA), p-Smad2 antibody (Cell Signaling, Beverly, MA,
USA), and thrombospondin (TSP Ab-8) (NeoMarkers)
(Lab Vision Co.). NP40208 is a novel 2,4-disubstituted
pteridine that inhibits the intracellular kinase domain of
the type I TGF-b receptor (TbR-I) (Scios, Inc., Sunny-
vale, CA, USA).
Cell culture
Rat proximal tubular epithelial cell line (NRK52E)
or fibroblasts derived from mouse embryo deficient in
Smad2 or Smad3 [24] were cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS), 60 lg/mL penicillin, and 100 lg/mL strep-
tomycin in 5% CO2 at 37◦C and media was changed every
3 days. Confluent cells were incubated for 24 hours with
0.5% FBS prior to stimulation. TGF-b1 was then added
to confluent cell at the designated concentrations for 0
to 24 hours. Endothelial basal media (EBM) media with
endothelial growth media (EGM)-MV (Cambrex, East
Rutherford, NJ, USA) was used to culture human umbil-
ical venous endothelial cell (HUVEC) (Cambrex).
Establishing doxycycline-regulated
Smad7-expression NRK52E cell lines
The doxycycline-regulated Smad7-expressing cell line
was established as described previously [25]. Briefly,
mouse Smad7 cDNA was subcloned using a tetracycline
(Tet)-inducible vector, pTRE (Clontech, Palo Alto, CA,
USA). An improved pTet-on vector, pEFpurop-Tet-on
[26], was used, in which the gene encoding the “reverse”
Tet repressor was subcloned into a pEF-BOS vector,
pEFr-PGKpuropAv18, thereby conferring puromycin re-
sistance [26]. To obtain doxycycline (a Tet derivative)–
induced Smad7-expressing NRK52E cell lines, pTRE-
Smad7 and pEFpurop-Tet-on were cotransfected into
NRK52E cells by electroporation, and then the sta-
ble transfected cells were selected in the presence of
puromycin (4 lg/mL). Doxycycline (4 lg/mL) was used
to induce Smad7. At least three experiments were per-
formed for each experiment. Cell viability in each experi-
mental condition was examined by lactate dehydrogenase
(LDH) assay with TOX-7 LDH Assay Kit (Sigma Chem-
ical Co., St. Louis, MO, USA).
RNAse protection assay (RPA)
Riboprobes were prepared as previously described
[27]. Briefly, rat VEGF-A (327 bp) was subcloned into
Bluescript SK+ (Stratagene, La Jolla, CA, USA). Af-
ter linearization, an antisense riboprobe was synthesized
with T7 polymerase in the presence of a-32P-labeled uri-
dine triphosphate (UTP). Total RNA was isolated with
RNeasy Kit (Qiagen, Valencia, CA, USA). Three mi-
crograms of total RNA samples were hybridized for
30 minutes at 90◦C with a mixture of 32P-UTP–labeled
riboprobes of rat VEGF-A and the housekeeping gene
(L32) (1 × 105 cpm for each probe), and RPA was
performed as described previously [27]. The protected
hybridized RNA was denatured at 85◦C and elec-
trophoresed on 10% polyacrylamide gels. The gels were
transferred to Whatman filter paper, dried, and exposed
to Kodak X-O mat film overnight at −70◦C.
Real time-polymerase chain reaction (PCR)
To quantify mRNA expression, real-time PCR was per-
formed. After 0.5 lg of total RNA was converted to
cDNA with Superscript II reverse transcriptase (Gibco
BRL, Gaithersburg, MD, USA), PCR was performed
with rat VEGF-A [28], TSP-1 [29] or GAPDH primers
[30] mixed with SYBR Green JumpStat Taq ReadyMix
(Sigma Chemical Co.) using a DNA Engine Opticon (MJ
Research, Waltham, MA, USA) as follows: 94◦C for 2
minutes, then 44 cycles of denaturation at 94◦C for 15 sec-
onds, annealing at 56◦C for 30 seconds, and extension at
72◦C for 20 seconds. Amplicon sizes were 492 bp (rat 164
VEGF-A), 360 bp (rat 120 VEGF-A), 379 bp (rat TSP-
1), and 299 bp (rat GAPDH). Reaction specificity was
confirmed by electrophoretic analysis of products prior
to real-time reverse transcription (RT)-PCR and bands
of expected size were detected. Ratios for either VEGF-
A/GAPDH mRNA or TSP-1/GAPDH mRNA were cal-
culated for each sample and expressed as mean ± SD.
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Enzyme-linked immunosorbent assay (ELISA)
for VEGF-A and sFlt-1 protein synthesis in
the supernatant of culture media
NRK52E cells were grown in six-well plates and cul-
ture supernatants were analyzed by Quantikine mouse
ELISA kit for VEGF-A or soluble Flt-1 (R& D Systems),
which cross-reacts with rat samples [31]. Total VEGF-A
or sFlt-1 protein (pg) in the supernatant was corrected by
cell protein content (lg) (Bio-Rad Protein Assay) (Bio-
Rad, Richmond, CA, USA).
Western blotting
Cells were washed in phosphate-buffered saline (PBS)
and then lysed in 100 lL of cell lysis buffer [20 mmol/L
Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1 mmol/L ethylene-
diaminetetraacetic acid (EDTA), 1 mmol/L ethylenegly-
col tetraacetate (EGTA), 1% Triton X-100, 2.5 mmol/L
sodium pyrophosphate, 1 mmol/L beta-glycerophos-
phate, and 1 mmol/L Na3VO4], containing a 1:50 dilu-
tion of a protease inhibitor cocktail (Pharmingen, San
Diego, CA, USA) for 30 minutes on ice. Samples were
centrifuged at 14,000g for 5 minutes to pellet cell debris.
To isolate nuclear proteins, cells from 100 mm dishes were
resuspended in 100lL 10 mmol/L Tris-HCl, 2 mmol/L
MgCl2, 5 mmol/L KCl, 10% glycerol, 1 mmol/L EDTA,
and 1 mmol/L dithiothreitol. NP40 (1%) was added
and cells allowed swelling on ice then vortexed. Lysates
were centrifuged (700g, 4◦C) and nuclear pellets resus-
pended in 30 lL 20 mmol/L HEPES, 0.4 mol/L NaCl,
1 mmol/L EDTA, 1 mmol/L EGTA, and 1 mmol/L dithio-
threitol before sonication. After determination of the
protein concentration using the Bio-Rad Protein Assay
(Bio-Rad), 30 lg of protein samples were mixed with
sample buffer (Invitrogen, Carlsbad, CA, USA), boiled,
resolved on NuPAGE Bis-Tris Gel (4% to 12%) gel, and
transferred to nitrocellulose membranes by electroblot-
ting. Membranes were blocked with 5% (wt/vol) bovine
serum albumin (BSA) in Tris-buffered saline with 0.1%
Triton (TBST) for 60 minutes at room temperature. Each
primary antibody was incubated at 4◦C overnight. Af-
ter washing with TBST, the membrane was rocked with
secondary antibody (antimouse IgG or anti rabbit IgG,
horseradish peroxidase-linked antibody) (Cell Signaling,
Beverly, MA, USA) for 60 minutes at room temperature.
The blot was then developed using the enhanced chemi-
luminescence (ECL) detection kit (Amersham Interna-
tional, Piscataway, NJ, USA) to produce a chemilumines-
cence signal, which was captured on x-ray film. Positive
immunoreactive bands were quantified by densitometry.
Endothelial cell proliferation assay
To further investigate the functional role of TGF-
b1/Smads in angiogenesis, we examined the angio-
genic effect of conditioned media of TGF-b1–stimulated
NRK52E cells or Smad2 and Smad3 knockout cells
on HUVEC. HUVEC (1 × 104) were cultured for 24
hours with conditioned media from either NRK52E
cell or Smad knockout cells, and endothelial cell num-
ber was determined using the methylthiazoletetrazolium
(MTT) Assay Kit (Sigma Chemical Co.). To block
the function of exogenous TGF-b1 in the conditioned
media, 50 nmol/L NP40208, a TbR-I inhibitor, (Scios
Inc.) was added to the conditioned media prior to
stimulation of HUVEC. In an in vitro kinase assay
NP40208 inhibits the TbR-I kinase with an IC50 of
0.048 lmol/L. When tested at 50 nmol/L the compound
has no effect on type II TbR kinase (data provided by
Scios Inc.). In our preliminary data, 50 nmol/L NP40208
inhibited VEGF-A expression in response to TGF-b1
(data not shown).
Statistical analysis
All values presented are expressed as mean ± SD.
Analysis of variance (ANOVA) followed by Bonferroni
correction was used in all instances. Significance was de-
fined as P < 0.05.
RESULTS
The effect of TGF-b1 on VEGF-A and TSP-1
induction in NRK52E cell
To examine the effects of TGF-b1 on the expression
of mRNA for VEGF-A or TSP-1 in NRK52E cells, ei-
ther RNAse protection assay for VEGF-A or real-time
PCR for TSP-1 were used. Five nanograms per milliliter
TGF-b1 increased both VEGF-A and TSP-1 mRNA in a
time-dependent manner and peaked at 24 hours (Fig. 1A
and B).
Both VEGF-A and TSP-1 protein were also increased
as early as 4 hours after incubation with 5 ng/mL TGF-b1
and progressively reached a maximum after 24 hours or
32 hours incubation, respectively (Fig. 1C and 1).
Dose-dependent effect of TGF-b1 on VEGF-A or
TSP-1 protein synthesis
To investigate the dose dependency of TGF-b1 on
VEGF-A or TSP-1 protein synthesis, NRK52E cells were
stimulated by TGF-b1 at concentrations of 0 to 5 ng/mL
for 24 hours, respectively, and VEGF-A protein in the
supernatant was measured by ELISA (Fig. 1E) while
Western blotting was used for TSP-1 synthesis (Fig. 1F).
VEGF-A protein expression was increased by 1 ng/mL
TGF-b1 in the supernatant of NRK52E cells. Higher
doses of TGF-b1 (5 ng/mL) enhanced more VEGF-A
protein expression (Fig. 1E). TSP-1 synthesis was also
stimulated in a dose-dependent manner (Fig. 1F).
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Fig. 1. Vascular endothelial growth factor
(VEGF-A) and thrombospondin-1 (TSP-1)
mRNA expression/protein synthesis induced
by transforming growth factor-b1 (TGF-
b1) in NRK52E cells. VEGF-A protein
in supernatant of culture media was mea-
sured by enzyme-linked immunosorbent as-
say (ELISA). TSP-1 protein was examined
by Western blotting. The protein expressions
were quantified by densitometry. (A) Time
course of VEGF-A mRNA expression by 5
ng/mL TGF-b1. L32 was used as a control.
(B) Time course of TSP-1 mRNA expression.
(C) Time course of VEGF-A protein synthe-
sis in supernatant of culture media by 5 ng/mL
TGF-b1. (D) Time course of TSP-1 protein
synthesis by 5 ng/mL TGF-b1. (E) Dose de-
pendency of VEGF-A protein synthesis in su-
pernatant of cultured media at 24 hours. (F)
Dose dependency of TSP-1 protein synthesis
at 24 hours. aP < 0.05 vs. 0 ng/mL TGF-b1;
bP < 0.01 vs. 0, 0.5, and 1 ng/mL TGF-b1.
GAPDH is glyceraldehyde-3-phosphate de-
hydrogenase.
R-Smads are critical for the expression of VEGF-A
and TSP-1 induced by TGF-b1
The R-Smads, Smad2 and Smad3, are known to play
a critical role in TGF-b1 signaling. To examine the col-
lective role of R-Smads on VEGF-A and TSP-1 expres-
sion by TGF-b1, we inhibited TGF-b-induced Smad2
and Smad3 activation by overexpressing the inhibitory
Smad, Smad7, using a doxycycline-inducible system in
the NRK52E cells. As shown in Figure 2A, TGF-b1–
induced Smad2 phosphorylation (determined by West-
ern blotting of whole cell lysates) was blocked by over-
expression of Smad7. Similarly, TGF-b1–induced Smad3
activation (determined by Western blotting of nuclear
protein as Smad3 translocates to the nucleus when ac-
tivated) was also blocked by Smad7 overexpression
(Fig. 2B). The inhibition of both R-Smads was associ-
ated with an inhibition of VEGF-A mRNA and protein
(Fig. 2C and E) and TSP-1 mRNA and protein (Fig. 2D
and F). The inhibition of mRNA expression for VEGF-A
and TSP-1 were observed as early as 2 hours (Fig. 2C and
D), and the reduction in protein was noted at 24 hours
(Fig. 2E and F). LDH assay and trypan blue staining did
not show any difference with doxycycline-Smad7 treat-
ment (data not shown). These findings suggest that TGF-
b1 directly stimulates VEGF-A and TSP-1 production,
which could be regulated by either Smad2 or Smad3, or
both.
We next examined whether the effects of TGF-b1
to induce VEGF-A and TSP-1 were mediated by in-
dividual R-Smads. To investigate the role of Smad3 in
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Fig. 2. The effect of overexpressing Smad7
in vascular endothesial growth factor (VEGF-
A)/thrombospondin-1 (TSP-1) expression in-
duced by transforming growth factor-b1
(TGF-b1) in NRK52E cells. (A) Doxycycline
(Dox)-induced Smad 7 inhibits the phospho-
rylation of Smad2 induced by TGF-b1 at 60
minutes. (B) Doxycycline-induced Smad7 in-
hibits the nuclear translocation of Smad3 in-
duced by TGF-b1 at 60 minutes. p62 was used
for control nuclear protein. (C) Doxycycline-
induced Smad7 inhibits the induction of
VEGF-A mRNA. (D) Dox-induced Smad7
suppresses TSP-1 mRNA expression in-
duced by TGF-b1. (E) Doxycycline-induced
Smad7 inhibits VEGF-A protein synthe-
sis at 24 hours. (F) Doxycycline-induced
Smad7 inhibits TSP-1 protein synthesis in-
duced by TGF-b1 at 24 hours. GAPDH is
glyceraldehyde-3-phosphate dehydrogenase.
VEGF-A/TSP-1 regulation, we examined the effect of
TGF-b1 on VEGF-A/TSP-1 in mouse fibroblasts ob-
tained from Smad3 knockout or wild-type mice. While
wild-type mouse fibroblasts synthesized VEGF-A pro-
tein in response to TGF-b , this was totally abrogated in
Smad3 knockout cells (Fig. 3A). In contrast, TSP-1 syn-
thesis was stimulated independent of Smad3 (Fig. 3B).
On the other hand, the absence of Smad2 abrogated
TSP-1 expression, whereas TSP-1 expression was in-
creased in Smad2 wild-type cell (Fig. 4B). In contrast,
TGF-b1–induced VEGF-A synthesis was not prevented
in Smad2 knockout cell (Fig. 4A).
These studies suggested a key role for Smad3 in medi-
ating TGF-b1–induced VEGF-A expression (a proangio-
genic molecule) whereas Smad2 was critical for TGF-b1–
induced TSP-1 expression (an antiangiogenic molecule).
To determine if this reflected a general mechanism that
separated the actions of these two Smads, we further
investigated whether Smad2 also mediated the produc-
tion of soluble VEGF-AR-1 (sFlt-1), which is now rec-
ognized as the natural antagonist of VEGF-A and which
may have a key role in preeclampsia and other condi-
tions [12, 13]. sFlt-1 was also stimulated by TGF-b in
NRK52E cell in a time- and dose-dependent manner
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Fig. 3. Role of Smad3 in regulation of vas-
cular endothelial growth factor (VEGF-A)
or thrombospondin-1 (TSP-1). (A) VEGF-A
protein synthesis in fibroblasts derived from
mouse embryo deficient in Smad3 [3 knockout
(3KO) or wild-type (3WT)] under basal con-
dition (con) or transforming growth factor-b1
(TGF-b1) stimulation at 8 hours. (B) TSP-1
protein synthesis in 3KO or 3WT under basal
condition or TGF-b1 stimulation at 24 hours.
TSP-1 and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) expressions were quan-
tified by densitometory.
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Fig. 4. Role of Smad2 in regulation of vas-
cular endothelial growth factor (VEGF-A)
or thrombospondin-1 (TSP-1). (A) VEGF-A
protein synthesis in fibroblasts derived from
mouse embryo deficient in Smad2 [2 knockout
(2KO) or wild-type (2WT)] under basal con-
dition (con) or transforming growth factor-b1
(TGF-b1) stimulation at 8 hours. (B) TSP-1
protein synthesis in 2KO or 2WT under basal
condition or TGF-b1 stimulation at 24 hours.
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Fig. 5. sFlt-1 protein synthesis induced by
transforming growth factor-b1 (TGF-b1) in
NRK52E cell and mouse fibroblast. sFlt-
1 protein was measured by enzyme-linked
immmunosorbent assay (ELISA). (A) Time
course of sFlt-1 protein synthesis under 5
ng/mL TGF-b1 stimulation. (B) Dose depen-
dency of sFlt-1 protein synthesis under TGF-
b1 stimulation at 8 hours. (C) sFlt-1 protein
synthesis in Smad2 [2 knockout (2KO) or
wild-type (2WT)] fibroblasts under basal con-
dition (con) or TGF-b1 stimulation at 8 hours.
(D) sFlt-1 protein synthesis in 3KO or 3WT
fibroblasts with or without TGF-b1 stimula-
tion at 8 hours. GAPDH is glyceraldehyde-3-
phosphate dehydrogenase.
(Fig. 5A and B). Consistent with the hypothesis, TGF-
b1 failed to enhance sFlt-1 production in Smad2 knock-
out cells (Fig. 5C), whereas the normal enhancement of
sFLT-1 was observed in Smad3 knockout cells (Fig. 5D).
Finally, to examine the functional roles of Smads in
angiogenesis/antiangiogenesis, we tested the effect of
conditional media, in which NRK52E, wild-type, Smad2
knockout, or Smad3 knockout fibroblasts had been
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Fig. 6. Endothelial cell proliferation assay.
(A) Human umbilical venous endothelial cells
(HUVEC) was stimulated by 20% serum me-
dia or conditioned media (24 hours) from
transforming growth factor-b1 (TGF-b1)-
stimulated NRK52E cells. (B) HUVEC were
stimulated by 20% serum media or con-
ditioned media (24 hours) from TGF-b1-
stimulated wild-type cell (WT), Smad3 knock-
out cell (3KO), and Smad2 knockout cell
(2KO). At 24 hours, cell number was mea-
sured by MTT assay (N = 8).
stimulated by TGF-b1 for 24 hours, on endothelial cell
proliferation at 24 hours. As shown in Figure 6A, condi-
tioned media from NRK52E cells did not induce HUVEC
proliferation. In contrast, Smad2 knockout-conditioned
media stimulated HUVEC proliferation while Smad3
knockout-conditioned media failed to stimulate pro-
liferation compared to wild-type–conditioned media
(Fig. 6B).
DISCUSSION
In this study, we report that TGF-b1 induces the syn-
thesis of angiogenic (VEGF-A) and antiangiogenic (TSP-
1 and sFLT-1) growth factors in proximal tubular cells
and fibroblasts. To dissect out the mechanism responsi-
ble for this stimulation, we investigated the roles of the
R-Smads (Smad2 and 3), which are known to be activated
by TGF-b1 in a variety of cell types. Both R-Smads were
shown to be activated in response to TGF-b1. To deter-
mine if the R-Smads played a critical role in TGF-b1 me-
diated synthesis of the growth factors, we blocked Smad2
and Smad3 phosphorylation by overexpressing the in-
hibitory Smad, Smad7, using a doxycycline-inducible
system. Overexpression of Smad7 blocked both the ex-
pression of VEGF-A and TSP-1 in proximal tubular cells
in response to TGF-b1. While these studies demonstrated
a key role for the R-Smads in this response, they did not
distinguish between Smad2 and Smad3. Using knockout
strategies, we were able to show that Smad2 and Smad3
play distinct but parallel roles in the stimulation of these
growth factors in response to TGF-b1. VEGF-A expres-
sion was regulated by Smad3, whereas Smad2 regulated
the expression of TSP-1 and sFlt-1. We have also recently
demonstrated similar patterns of regulation of VEGF-A
and TSP-1 in NRK52E cells using antisense strategies
(data not shown).
Interestingly, the conditioned media from NRK52E
did not show any proliferative effect on endothelial
cells, which could relate to the release of both an-
giogenic and antiangiogenic factors that neutralize the
effect of each other. To dissect this mechanism fur-
ther, we examined the effect of conditioned media
from Smad3 and Smad2 knockout fibroblasts following
TGF-b1 stimulation. Smad2 knockout-conditioned me-
dia stimulated endothelial cell proliferation compared to
wild-type–conditioned media whereas Smad3 knockout–
conditioned media resulted in less proliferation than
wild-type–conditioned media. These data are thus con-
sistent with the observations that Smad3 knockout media
has minimal VEGF-A but more TSP-1 and sFlt1, whereas
Smad2 knockout media has less TSP-1 and sFLT-1 and
more VEGF-A.
These findings provide the first demonstration, to our
knowledge, that the R-Smads have distinct and opposite
effects on angiogenesis, with Smad3 stimulating the pro-
duction of angiogenic factors, whereas Smad2 stimulated
the production of antiangiogenic factors. This could have
important implications in the often conflicting data re-
lated to the role of TGF-b1 on angiogenesis and antian-
giogenesis [32–37].
One of the major signaling pathways through which
TGF-b1 acts is by activating Smads. In this regard, both
Smad2 and Smad3 are known to be activated by TGF-
b1, and it has been previously thought that they work in
union to stimulate extracellular matrix production, apop-
tosis, and the development of fibrosis [23, 25, 38, 39]. On
the other hand, Smad7, inhibitory Smad, can inhibit the
activation of Smad2 and 3. In this study, overexpression
of Smad7 blocked the expression of both VEGF-A and
TSP-1 in response to TGF-b1, consistent for a role for
Smad 2 and/or Smad 3 in their regulation. However, the
inhibition of VEGF-A and TSP-1 by overexpression of
Smad 7 was incomplete, suggesting that other pathways,
such as mitogen-activated protein kinases (MAPKs), may
be involved. Indeed, our preliminary data have shown
that both the extracellular signal-related kinase (ERK)
as well as p38 MAPKs also partially regulate the expres-
sion of these two growth factors in response to TGF-b1
(data not shown).
In this study, we report that Smad3 is proangiogenic.
Specifically, we found that Smad3 is a critical intracel-
lular signaling molecule mediating TGF-b1–stimulated
VEGF-A expression. Smad3 has been previously re-
ported to regulate VEGF-A expression in COS cells [40].
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However, it is also important to clarify VEGF-A regu-
lation in resident renal cells since VEGF-A expression
in the kidney has a critical role in maintaining capillary
structure and viability, and loss of VEGF-A results in
glomerular injury [41] and progressive renal damage [1,
2, 42]. Interestingly, TSP-1 as well as sFlt-1 expression
were enhanced in Smad3 knockout cell in response to
TGF-b1, suggesting that Smad3 could also inhibit the ex-
pression of these antiangiogenic factors, in addition to
enhance VEGF-A expression.
In contrast, we found that Smad2 was critical in the pro-
duction of antiangiogenic factors in response to TGF-b1.
Both TSP-1 and sFLT-1 were induced through Smad2-
dependent pathways. This could provide an additional
mechanism by which TGF-b1 could accelerate progres-
sive renal disease, as production of these growth factors
have been shown to be highly linked with renal injury
[14] and progression [10, 11, 29].
Conditioned media from NRK52E cells did not in-
duce endothelial proliferation. It could be because both
VEGF-A, an angiogenic factor, and TSP-1, an antiangio-
genic factor, were contained in the conditioned media.
Consistent with this possibility was the observation that
conditioned media from Smad2 knockout cells but not
Smad3 knockout cells stimulated endothelial prolifera-
tion, as Smad2 knockout cells produce more VEGF-A
and less TSP-1 than the Smad3 knockout cells. In addition
to the divergent effect of TGF-b1 on angiogenic and an-
tiangiogenic growth factors produced by the tubular cell
and the fibroblast, TGF-b1 also regulates angiogenesis
by direct effects on endothelial cell proliferation and also
by modulating expression of the VEGF receptor on the
endothelial cell. Indeed, it has been shown that TGF-b1
down-regulates kinase-inserted domain receptor (KDR)
in endothelial cell [43] while hypoxia induces KDR [44]
or Flt-1 [45]. These data suggest that TGF-b1 is a com-
plex molecule with multiple mechanisms by which it can
regulate angiogenesis.
Only recently has it been appreciated that the R-
Smads may have distinct functions. Smad2 knockout mice
are embryonically lethal [46], whereas Smad3 knockout
mice remain viable [47]. Smad2 has also been shown
to mediate production of matrix metalloproteinase 2,
whereas the induction of c-fos, Smad7, and TGF-b1 au-
toinduction are dependent on Smad3 [24].
With respect to other Smads, it has been recently re-
ported that Smad4 may also have an antiangiogenic role
[48]. Overexpression of Smad4 in pancreatic adenocar-
cinoma cells led to decreased expression of VEGF and
increasing expression of TSP-1 [48]. Interestingly, al-
though TGF-b could increase expression of both factors,
this Smad4-mediated difference in expression levels was
maintained in cell overexpressing Smad4 [48]. These data
suggest Smad4 may also have antiangiogenic actions. Fu-
ture studies will be needed to investigate the interrelation
of Smad4 with the R-Smads in the angiogenic response.
CONCLUSION
Our results demonstrate that R-Smads play distinct
and opposing roles in regulating angiogenic factors. Fur-
ther studies are necessary to determine if selective activa-
tion of these Smads may account for the different angio-
genic responses observed in conditions in which TGF-b1
is expressed.
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